Latest
-
Covid-19 vaccines helped these stocks take off, but what’s next for these companies?
Tips Dominic Frisby explores how the top vaccine stocks are doing as booster take-up remains at a low
Tips -
Why this biotech company has years of growth ahead
Analysis Zimmer Biomet, a leader in the worldwide market for hip and knee joints, enjoys a competitive advantage and has years of growth ahead, says Dr Mike Tubbs.
Analysis -
Are GSK’s legal troubles a threat to the firm’s survival?
Analysis Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargreaves looks at how it might affect the business's prospects.
Analysis -
The mistakes pharmaceutical companies made with their Covid vaccines
Opinion Covid-19 looked as if it would mark the start of a golden age for the pharmaceutical industry. It’s not worked out that way, says Matthew Lynn.
Opinion -
How Covid-19 changed biotechnology – and how you can invest
Cover Story The pandemic has exacted a huge human and financial toll, but it has also transformed scientific research in ways that will deliver huge benefits for healthcare. Matthew Partridge reports.
Cover Story -
The best vaccine-makers’ stocks to buy now
Cover Story The rapid development of Covid-19 vaccines has already saved many lives and made huge profits for a few pharmaceutical firms. Investors should keep an eye on other products in their pipelines, says Dr Mike Tubbs.
Cover Story -
The huge potential of mRNA technology
Briefings The new technology made its name when it delivered Covid-19 vaccines in record time. But it could be pressed into use in many other areas too. Simon Wilson reports.
Briefings -
AstraZeneca’s Covid troubles could see it pull out of making vaccines
News AstraZeneca has suffered a series of setbacks with its Covid-19 jab and may exit the inoculation subsector altogether. Matthew Partridge reports
News -
A great leap forward in the war against Alzheimer’s disease
Cover Story The approval of the first drug to treat the neurodegenerative disease in 18 years will galvanise research in the entire subsector, says Dr Mike Tubbs. That bodes well for Huntingdon’s and Parkinson’s sufferers too
Cover Story
